A prominent neuroscientist has developed the Quick Dementia Rating System to reliably, and quickly, identify patients suffering from dementia.
Developed by James E. Galvin, MD, MPH, the Quick Dementia Rating System (QDRS) uses an evidence-based method to accurately identify and stage patients with dementia. QDRS has applications for use in clinical practice, to prequalify patients in clinical trials, prevention studies, community surveys and biomarker research.
The existing process to evaluate individuals is long and laborious, while QDRS has the advantage of being conducted in a few minutes. "After extensive testing and evaluation of the Quick Dementia Rating System, we have found it to be as effective as the gold standard used today to screen for the five stages of dementia," said Dr Galvin. "This new tool gives you a lot of power to see the same results as a full screening in a fraction of the time it takes for a complete screening." The findings with QDRS have been published in the journal Alzheimer's and Dementia.
The evaluation includes a 10-item questionnaire that can be completed by a caregiver, friend, or family member, and is short enough to be viewed as a single screenshot, maximizing its clinical utility. Scores range from 0 to 30 with higher scores representing greater cognitive impairment. The questionnaire covers: 1) memory and recall; 2) orientation; 3) decision-making and problem-solving abilities; 4) activities outside the home; 5) function at home and hobbies; 6) toileting and personal hygiene; 7) behavior and personality changes; 8) language and communication abilities; 9) mood; and 10) attention and concentration.
Read more at EurekAlert!: http://bit.ly/1ErZzAH
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More